Nicholas A. Meanwell is currently an adjunct professor at The Baruch S. Blumberg Institute, The University of Michigan, and Rutgers University. He received his PhD from the University of Sheffield and conducted postdoctoral studies at Wayne State University before joining Bristol Myers Squibb in 1982. He currently is affiliated with The Baruch S. Blumberg Institute, Doylestown, PA, the Department of Medicinal Chemistry; College of Pharmacy at The University of Michigan, Ann Arbor, and the Ernest Mario School of Pharmacy at Rutgers, New Brunswick, NJ. He has been associated with the discovery of BMY-433771, an inhibitor of respiratory syncytial virus fusion, the HIV-1 attachment inhibitor temsavir/fostemsavir, the HIV-1 maturation inhibitor GSK-3532795/BMS-955176, and the marketed HCV inhibitors asunaprevir (NS3), daclatasvir (NS5A), and beclabuvir (NS5B). He is the corecipient of a 2014 PhRMA Research and Hope Award for Biopharmaceutical Industry Research and ACS Heroes of Chemistry Awards in 2017 and 2023. He was the recipient of the 2015 Philip S. Portoghese Medicinal Chemistry Lectureship Award, the 2024 Antonín Holý Memorial Award and was inducted into the ACS Division of Medicinal Chemistry Hall of Fame in 2015.